Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Slides:

Advertisements

Similar presentations

The Principles of Engineering Immune Cells to Treat Cancer

Advertisements

Volume 12, Issue 5, Pages (November 2005)

Volume 20, Issue 2, (February 2012)

Molecular Therapy - Oncolytics

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Jacques F.A.P. Miller, Michel Sadelain Cancer Cell

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Engineering Natural Killer Cells for Cancer Immunotherapy

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Genome-editing Technologies for Gene and Cell Therapy

Figure 1 Chimeric antigen receptor (CAR) structures

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Identification of the Tumor Cells in Peripheral T-Cell Lymphomas by Combined Polymerase Chain Reaction-Based T-Cell Receptor β Spectrotyping and Immunohistological.

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,

Engineering T Cells to Functionally Cure HIV-1 Infection

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Daniel Abate-Daga, Marco L Davila Molecular Therapy - Oncolytics

Direct Conversion of Skin Cells into Blood: Alchemy or Science?

Volume 22, Issue 3, Pages (March 2014)

Miki Ando, Hiromitsu Nakauchi Experimental Hematology

Engineering Natural Killer Cells for Cancer Immunotherapy

HIV Receives a “One Two Knockout Punch”

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

Like Angler Fish, CAARs Lure Their Prey

Xiuyan Wang, Isabelle Rivière Molecular Therapy - Oncolytics

A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer

The Other Face of Chimeric Antigen Receptors

Volume 3, Issue 5, Pages (May 2003)

Volume 23, Issue 4, Pages (April 2015)

Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation” Andreas A Hombach, Gunter.

Research Techniques Made Simple: CAR T-Cell Therapy

Genome-editing Technologies for Gene and Cell Therapy

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

The Principles of Engineering Immune Cells to Treat Cancer

Premal Lulla, Carlos A. Ramos Molecular Therapy

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Designer Lipids Advance Systemic siRNA Delivery

Volume 21, Issue 4, Pages (April 2013)

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

KIT in Melanoma: Many Shades of Gray

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Volume 26, Issue 4, Pages (April 2018)

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Chimeric antigen receptor T-cell therapy for solid tumors

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Volume 21, Issue 5, Pages (May 2013)

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Circulating Tumor Cells and Detection of the Melanoma-Associated Antigen HMW-MAA in the Serum of Melanoma Patients Anja Ulmer, Gerhard Fierlbeck Journal.

773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Volume 24, Issue 2, Pages (February 2016)

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Genetically modified TCRs for cancer immunotherapy.

History of Oncolytic Viruses: Genesis to Genetic Engineering

Cell-Intrinsic Barriers of T Cell-Based Immunotherapy

Gene targeting: Applications in transplantation research

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

Morton J Cowan, Hans-Peter Kiem Molecular Therapy

CAR T cell immunotherapy for human cancer

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma? Rajasekharan Somasundaram, Jessie Villanueva, Meenhard Herlyn Molecular Therapy Volume 19, Issue 4, Pages 638-640 (April 2011) DOI: 10.1038/mt.2011.46 Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Polyclonal T cells expressing CD20 svFv-CAR acquire redirected specificity to lyse melanoma tumor cell subset. T cells were engineered to express a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv), derived from a combining region of a monoclonal antibody directed against CD20 and fused to a CD3z signaling domain of a T-cell receptor (TCR). Engineered T cells have a redirected specificity to target and lyse a CD20+ subset of melanoma cells without human leukocyte antigen (HLA) restriction. HMW-MAA, high-molecular-weight–melanoma-associated antigen. Molecular Therapy 2011 19, 638-640DOI: (10.1038/mt.2011.46) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions